Manufacturer of Controlled Substances; Notice of Application, 24313 [E8-9696]

Download as PDF 24313 Federal Register / Vol. 73, No. 86 / Friday, May 2, 2008 / Notices to be issued by the Commission no later than the publication in the Federal Register of such determinations by the Department of Commerce.’’ Subsequently, the Department of Commerce extended the date for its final determination in the investigation on Mexico to June 13, 2008 (73 FR 10743, February 28, 2008). The Commission is, hereby, issuing its additional scheduling date with respect to the investigations concerning China, Korea, and Mexico as follows: a supplemental brief addressing only Commerce’s final countervailing and antidumping duty determinations is due on June 20, 2008. The brief may not exceed five (5) pages in length. For further information concerning these investigations see the Commission’s notice cited above and the Commission’s Rules of Practice and Procedure, part 201, subparts A through E (19 CFR part 201), and part 207, subparts A and C (19 CFR part 207). Authority: These investigations are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.21 of the Commission’s rules. By order of the Commission. Issued: April 28, 2008. Marilyn R. Abbott, Secretary to the Commission. [FR Doc. E8–9665 Filed 5–1–08; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE mstockstill on PROD1PC66 with NOTICES Notice of Lodging of Consent Decree Under the Clean Air Act Notice is hereby given that on April 24, 2008, a proposed Consent Decree (‘‘Decree’’) in United States v. McCulloch Corporation, et al., Civil Action No. 1:08–cv–00699, was lodged with the United States District Court for the District of Columbia. In this action the United States, on behalf of the U.S. Environmental Protection Agency (‘‘U.S. EPA’’), sought penalties and injunctive relief under sections 204, 205, and 213 of the Clean Air Act (‘‘the Act’’ or ‘‘CAA’’), 42 U.S.C. 7523, 7524, and 7547, and regulations promulgated thereunder at 40 CFR part 90 (‘‘Nonroad SI Regulations’’), which arose from the importation and introduction into commerce of approximately 200,000 chainsaws (‘‘subject chainsaws’’) that failed to comply with the Nonroad SI Regulations. The proposed Decree resolves alleged violations of the CAA arising from the importation of the subject chainsaws. Under the Decree, Defendants will pay a $2 million civil VerDate Aug<31>2005 17:17 May 01, 2008 Jkt 214001 penalty, export unsold chainsaws, perform emissions testing on a representative sampling of engines, and implement robust compliance assurance plans designed to prevent future violations. Defendants will also perform the following three mitigation projects at an estimated cost of $5 million: (1) Spend at least $2.75 million to provide light-emitting diode (‘‘LED’’) streetlights, sport lights or parking lot lights to selected cities in the United States, (2) spend at least $1.25 million to purchase and then surrender to U.S. EPA Ozone Season NOX Allowances, and (3) install low-permeable fuel lines that will prevent or reduce volatile organic compound permeation emissions in at least 1 million small, spark-ignited engines used for handheld lawn and garden applications. The Department of Justice will receive for a period of thirty (30) days from the date of this publication comments relating to the Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, P.O. Box 7611, U.S. Department of Justice, Washington, D.C. 20044–7611, and either e-mailed to pubcomment-ees.enrd@usdoj.gov or mailed to P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611, and should refer to United States v. McCulloch Corporation et al., D.J. Ref. 90–5–2–1–09103. The Decree may be examined at U.S. EPA, Office of Enforcement and Compliance Assurance, Western Field Office (8MSU), 1595 Wynkoop Street, Denver, CO 80202. During the public comment period, the Decree may also be examined on the following Department of Justice Web site, http:// www.usdoj.gov/enrd/Consent_ Decrees.html. A copy of the Decree may also be obtained by mail from the Consent Decree Library, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611 or by faxing or emailing a request to Tonia Fleetwood (tonia.fleetwood@usdoj.gov), fax no. (202) 514–0097, phone confirmation number (202) 514–1547. In requesting a copy from the Consent Decree Library, please enclose a check in the amount of $16.25 (25 cents per page reproduction cost) payable to the U.S. Treasury or, if by e-mail or fax, forward a check in that amount to the Consent Decree Library at the stated address. DEPARTMENT OF JUSTICE Karen Dworkin, Assistant Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. E8–9677 Filed 5–1–08; 8:45 am] Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 2, 2008, Lin Zhi International Inc., 687 North Pastoria Avenue, Sunnyvale, California 94085, made application by renewal to BILLING CODE 4410–15–P PO 00000 Frm 00103 Fmt 4703 Sfmt 4703 Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 3, 2008, Abbott Laboratories, DBA Knoll Pharmaceutical Company, 30 North Jefferson Road, Whippany, New Jersey 07981, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Dihydromorphine (9145) ............... Hydromorphone (9150) ................ Schedule I II The company plans to manufacture bulk product and dosage units for distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR § 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than July 1, 2008. Dated: April 28, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–9696 Filed 5–1–08; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application E:\FR\FM\02MYN1.SGM 02MYN1

Agencies

[Federal Register Volume 73, Number 86 (Friday, May 2, 2008)]
[Notices]
[Page 24313]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-9696]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on April 3, 2008, Abbott 
Laboratories, DBA Knoll Pharmaceutical Company, 30 North Jefferson 
Road, Whippany, New Jersey 07981, made application by renewal to the 
Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances listed in 
schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Dihydromorphine (9145).....................  I
Hydromorphone (9150).......................  II
------------------------------------------------------------------------

    The company plans to manufacture bulk product and dosage units for 
distribution to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration pursuant to 21 CFR Sec.  
1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administration, Office of Diversion Control, Federal Register 
Representative (ODL), Washington, DC 20537, or any being sent via 
express mail should be sent to Drug Enforcement Administration, Office 
of Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than July 1, 2008.

    Dated: April 28, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E8-9696 Filed 5-1-08; 8:45 am]
BILLING CODE 4410-09-P